EAHAD

EAHAD 2026 Congress
2026-02-03 - 2026-02-06 | The Convention Centre Dublin, Spencer Dock, N Wall Quay, North Wall, Dublin 1, D01 T1W6, Ireland, Dublin, Ireland

Revisiting the role of FVIII in Haemophilia A in 2026
2026-04-06 | EAHAD Academy
Cedric Hermans sits down with Jan Blatný, Consultant Haematologist at Masaryk University and University Hospital Brno, EHCC and EuroBloodNet Centre, and former EAHAD President (2024–2026), to explore the evolving role of Factor VIII in the management of haemophilia A in 2026. As new therapies such as emicizumab, rebalancing agents, and gene therapy reshape the treatment landscape, this conversation revisits where FVIII remains essential.

Clinical Implications of Roctavian’s Market Withdrawal
2026-04-07 17:30 - 18:30 (Europe/Brussels) | Online
The recent withdrawal of Roctavian from the market has raised important questions for clinicians, patients, and healthcare systems involved in the management of haemophilia A gene therapy. As the first approved GT medicine for adults with severe haemophilia A, Roctavian represented a significant milestone in the evolution of treatment options, and the effects of its withdrawal remain to be seen. This online session explores the clinical implications of its withdrawal, including considerations for patient management, ongoing monitoring of treated individuals, and the broader impact on the future of gene therapy in haemophilia.

Watch this insightful discussion on what this development means for clinical practice and the haemophilia community.

E-Learning Module 22: Connecting the Dots: How Hemophilia Guidelines Drive Practice, Policy, and Access
2026-04-10 | EAHAD Academy

WFH Congress
2026-04-10 - 2026-04-16 | Kuala Lumpur, Malaysia, Malaysia
The WFH 2026 World Congress will include over 80 hours of continuing educational sessions across the Medical and People with Bleeding Disorders (PWBD) tracks, as well as six professional development tracks: Nursing, Dental, Laboratory Sciences, Psychosocial, Musculoskeletal (MSK) and Women and Girls with Bleeding Disorders (WGBD).

EHA2026 Congress
2026-06-11 - 2026-06-14 | Stockholm, Sweden, Sweden
The European Hematology Association (EHA) community consists of doctors (haematologists), researchers (PhD or otherwise), patients (and advocacy groups), geneticists, nurses, and more mainly across Europe, including non-EU member states.

Inhibitor Development in Gene Therapy for Haemophilia
2026-06-15 17:00 - 18:00 | Online
Gene therapy is transforming the treatment landscape of hemophilia, but major questions remain regarding its use in patients with current or past inhibitors. In this webinar, leading experts will discuss the most challenging clinical and immunological questions, from mechanisms of liver-induced tolerance to the management of inhibitors developing after gene transfer, and will debate whether eligibility criteria should evolve in light of emerging data.

ISTH 2026
2026-07-11 - 2026-07-15 | Paris, France, France
ISTH is a worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and haemostasis.

EHC Conference 2026
2026-10-02 - 2026-10-04 | Istambul
